STAT+: Pfizer’s Lyme vaccine results set up tricky regulatory path
Why it matters: A highly effective Lyme vaccine faces a tricky regulatory path, impacting public health and vaccine accessibility.
- Pfizer and Valneva's Lyme vaccine cut cases by 73% in a Phase 3 trial, showing meaningful effectiveness (STAT+).
- The vaccine missed its primary statistical endpoint due to the confidence interval falling below the pre-specified threshold, complicating regulatory review despite overall solid data and safety (STAT+ Matthew Herper, Pharmalittle).
- A new Parkinson’s startup is developing personalized neuron replacement therapies (STAT+).
- Insmed is working to expand the use of Arikayce earlier in disease treatment (STAT+).
- Apogee is touting a longer-lasting drug for eczema (STAT+).
- Geopolitical tensions are beginning to strain drug supply chains, a concern also noted by Pharmalittle (STAT+).
Pfizer and Valneva's Lyme disease vaccine demonstrated significant efficacy, reducing cases by 73% in a Phase 3 trial, yet it narrowly missed its primary statistical endpoint, creating a complex path for regulatory approval despite strong safety data. This statistical hurdle, highlighted across multiple STAT News reports, could complicate the vaccine's journey to market, even as other biopharma innovations like personalized Parkinson's treatments and longer-lasting eczema drugs advance.
